GlobeNewswire - Industry News on Biotechnology http://www.10gbhost.com/RssFeed/industry/4573-Biotechnology/feedTitle/GlobeNewswire%20-%20Industry%20News%20on%20Biotechnology Contains the last 20 releases newsdesk@globenewswire.com (NewsDesk) Fri, 05 Feb 2021 22:36:08 GMT webmaster@globenewswire.com (Webmaster) http://www.10gbhost.com/news-release/2021/02/05/2170934/0/en/Equillium-Announces-Closing-of-30-Million-Registered-Direct-Offering.html http://www.10gbhost.com/news-release/2021/02/05/2170934/0/en/Equillium-Announces-Closing-of-30-Million-Registered-Direct-Offering.html Nasdaq:EQ FI0009008676 Equillium Announces Closing of $30 Million Registered Direct Offering LA JOLLA, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the closing of its previously announced registered direct offering with life science institutional investment funds managed by Decheng Capital, to purchase 4,285,710 units (the “Units”) from Equillium, with each Unit consisting of one share of common stock and a warrant to purchase 0.3 of a share of common stock. The purchase price per Unit was $7.00, priced above the market under Nasdaq rules. The warrants have an exercise price of $14.00 per share, are immediately exercisable, and will expire on the earlier of (i) the fifth anniversary of issuance, or (ii) the 15th calendar date following the date on which Equillium closes a financing raising a minimum of $25 million at a price per share of no less than $25.00.? ?

]]>
Fri, 05 Feb 2021 22:36 GMT 2170934 en GlobeNewswire Inc. Equillium, Inc. Fri, 05 Feb 2021 22:36 GMT Stock Market News
http://www.10gbhost.com/news-release/2021/02/05/2170927/0/en/Pacific-Biosciences-Grants-Equity-Incentive-Award-to-New-Employee.html http://www.10gbhost.com/news-release/2021/02/05/2170927/0/en/Pacific-Biosciences-Grants-Equity-Incentive-Award-to-New-Employee.html Nasdaq:PACB US69404D1081 Pacific Biosciences Grants Equity Incentive Award to New Employee MENLO PARK, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of Pacific Biosciences common stock and restricted stock units (“RSU”) covering 50,000 shares of Pacific Biosciences common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan on December 14, 2020 (the “2020 Inducement Plan”).

]]>
Fri, 05 Feb 2021 22:00 GMT 2170927 en GlobeNewswire Inc. Pacific Biosciences of California, Inc. Fri, 05 Feb 2021 22:00 GMT Product / Services Announcement Stock Market News
http://www.10gbhost.com/news-release/2021/02/05/2170908/0/en/argenx-announces-closing-of-global-offering.html http://www.10gbhost.com/news-release/2021/02/05/2170908/0/en/argenx-announces-closing-of-global-offering.html Brussels:ARGX Nasdaq:ARGX NL0010832176 US04016X1019 argenx announces closing of global offering Regulated information

]]>
Fri, 05 Feb 2021 21:01 GMT 2170908 en GlobeNewswire Inc. argenx SE Fri, 05 Feb 2021 21:01 GMT Other News European Regulatory News
http://www.10gbhost.com/news-release/2021/02/05/2170888/0/en/Amendment-Trading-by-management-and-close-relations-of-management.html http://www.10gbhost.com/news-release/2021/02/05/2170888/0/en/Amendment-Trading-by-management-and-close-relations-of-management.html Copenhagen:NZYM B DK0060336014 Amendment: Trading by management and close relations of management Please read the full announcement in?PDF

]]>
Fri, 05 Feb 2021 19:17 GMT 2170888 en GlobeNewswire Inc. Novozymes A/S Fri, 05 Feb 2021 19:17 GMT Insider's Buy/Sell European Regulatory News
http://www.10gbhost.com/news-release/2021/02/05/2170885/0/en/TG-Therapeutics-Announces-FDA-Accelerated-Approval-of-UKONIQ-umbralisib.html http://www.10gbhost.com/news-release/2021/02/05/2170885/0/en/TG-Therapeutics-Announces-FDA-Accelerated-Approval-of-UKONIQ-umbralisib.html Nasdaq:TGTX US88322Q1085 TG Therapeutics Announces FDA Accelerated Approval of UKONIQ? (umbralisib) UKONIQ is approved for adult patients with relapsed or refractory marginal zone lymphoma after at least one prior anti-CD20 based regimen

]]>
Fri, 05 Feb 2021 18:55 GMT 2170885 en GlobeNewswire Inc. TG Therapeutics, Inc. Fri, 05 Feb 2021 18:55 GMT Health
http://www.10gbhost.com/news-release/2021/02/05/2170860/0/en/Valneva-D%C3%A9claration-d-actions-et-de-droits-de-vote-Janvier-2021.html http://www.10gbhost.com/news-release/2021/02/05/2170860/0/en/Valneva-D%C3%A9claration-d-actions-et-de-droits-de-vote-Janvier-2021.html Paris:VLA Paris:VLAP FR0004056851 FR0011472943 Valneva - Déclaration d’actions et de droits de vote – Janvier 2021 VALNEVA

]]>
Fri, 05 Feb 2021 17:00 GMT 2170860 en GlobeNewswire Inc. VALNEVA Fri, 05 Feb 2021 17:00 GMT Law & Legal Issues European Regulatory News
http://www.10gbhost.com/news-release/2021/02/05/2170844/0/en/Bright-Minds-Biosciences-Announces-Listing-on-Canadian-Stock-Exchange.html http://www.10gbhost.com/news-release/2021/02/05/2170844/0/en/Bright-Minds-Biosciences-Announces-Listing-on-Canadian-Stock-Exchange.html CNSX:DRUG CA10919W1086 Bright Minds Biosciences Announces Listing on Canadian Stock Exchange VANCOUVER, British Columbia, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds” or the “Company”), a biosciences company focused on creating the next generation of psychedelic and related therapies for the treatment of mental health and central nervous system disorders, today announced that the Company’s common shares (the “Shares”) are expected to commence trading on the Canadian Securities Exchange (the “CSE”) on Monday, February 8, 2021, under the ticker symbol “DRUG.”

]]>
Fri, 05 Feb 2021 16:30 GMT 2170844 en GlobeNewswire Inc. Bright Minds Biosciences Fri, 05 Feb 2021 16:30 GMT Initial Public Offerings
http://www.10gbhost.com/news-release/2021/02/05/2170739/0/en/Denali-Therapeutics-to-Present-New-Data-on-ETV-IDS-DNL310-for-the-Potential-Treatment-of-Hunter-Syndrome-at-WORLDSymposium.html http://www.10gbhost.com/news-release/2021/02/05/2170739/0/en/Denali-Therapeutics-to-Present-New-Data-on-ETV-IDS-DNL310-for-the-Potential-Treatment-of-Hunter-Syndrome-at-WORLDSymposium.html Nasdaq:DNLI US24823R1059 Denali Therapeutics to Present New Data on ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at WORLDSymposium? – Management to host webinar for analysts on Friday, Feb. 12, at 8:00 a.m. Eastern Time –]]> Fri, 05 Feb 2021 14:00 GMT 2170739 en GlobeNewswire Inc. Denali Therapeutics Inc. Fri, 05 Feb 2021 14:00 GMT Calendar of Events Health biotechnology Biotech Neurodegeneration clinical trials Denali Therapeutics Hunter Syndrome MPSII blood-brain barrier http://www.10gbhost.com/news-release/2021/02/05/2170706/0/en/Angion-Biomedica-Corp-Announces-Pricing-of-Initial-Public-Offering-of-Common-Stock-and-Concurrent-Private-Placement.html http://www.10gbhost.com/news-release/2021/02/05/2170706/0/en/Angion-Biomedica-Corp-Announces-Pricing-of-Initial-Public-Offering-of-Common-Stock-and-Concurrent-Private-Placement.html Nasdaq:ANGN TEMP12345678 Angion Biomedica Corp. Announces Pricing of Initial Public Offering of Common Stock and Concurrent Private Placement UNIONDALE, N.Y., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced the pricing of its initial public offering on February 4, 2021 of 5,000,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $80,000,000 million, before deducting the underwriting discounts and commissions and offering expenses. All of the shares of common stock are being offered by Angion. Angion has also granted the underwriters a 30-day option to purchase from Angion up to an additional 750,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Angion’s common stock has been approved for listing on The Nasdaq Global Select Market and is expected to begin trading under the ticker symbol “ANGN” on February 5, 2021. The offering is expected to close on February 9, 2021, subject to satisfaction of customary closing conditions.

]]>
Fri, 05 Feb 2021 13:30 GMT 2170706 en GlobeNewswire Inc. Angion Biomedica Corp. Fri, 05 Feb 2021 13:30 GMT Initial Public Offerings Stock Market News Changes in company's own shares IPO Initial Public Offering San Francisco Boston New York kidney lung transplant
http://www.10gbhost.com/news-release/2021/02/05/2170666/0/en/CRISPR-Therapeutics-to-Participate-in-the-Guggenheim-Healthcare-Talks-2021-Oncology-Day.html http://www.10gbhost.com/news-release/2021/02/05/2170666/0/en/CRISPR-Therapeutics-to-Participate-in-the-Guggenheim-Healthcare-Talks-2021-Oncology-Day.html Nasdaq:CRSP CH0334081137 CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Guggenheim Healthcare Talks 2021 Oncology Day on Friday, February 12, 2021, at 3:30 p.m. ET.

]]>
Fri, 05 Feb 2021 13:00 GMT 2170666 en GlobeNewswire Inc. CRISPR Therapeutics AG Fri, 05 Feb 2021 13:00 GMT Calendar of Events Health
http://www.10gbhost.com/news-release/2021/02/05/2170671/0/en/Soleno-Therapeutics-Provides-Recap-of-Key-Opinion-Leader-Webinar-on-DCCR-for-Treatment-of-Prader-Willi-Syndrome.html http://www.10gbhost.com/news-release/2021/02/05/2170671/0/en/Soleno-Therapeutics-Provides-Recap-of-Key-Opinion-Leader-Webinar-on-DCCR-for-Treatment-of-Prader-Willi-Syndrome.html Nasdaq:SLNO US8342032005 Soleno Therapeutics Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome Recent analysis of Phase 3 DESTINY PWS limited to data collected before the onset of the COVID-19 pandemic shows statistical significance in the primary and key secondary endpoints]]> Fri, 05 Feb 2021 13:00 GMT 2170671 en GlobeNewswire Inc. Soleno Therapeutics Fri, 05 Feb 2021 13:00 GMT Health http://www.10gbhost.com/news-release/2021/02/05/2170609/0/en/Silence-Therapeutics-plc-Announces-45-Million-Private-Placement.html http://www.10gbhost.com/news-release/2021/02/05/2170609/0/en/Silence-Therapeutics-plc-Announces-45-Million-Private-Placement.html LSE:SLN Nasdaq:NASDAQ: SLN GB00B9GTXM62 Silence Therapeutics plc Announces $45 Million Private Placement THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. IN ADDITION, MARKET SOUNDINGS WERE TAKEN IN RESPECT OF THE MATTERS CONTAINED IN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF SUCH INSIDE INFORMATION. UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION OF INSIDE INFORMATION.

]]>
Fri, 05 Feb 2021 12:00 GMT 2170609 en GlobeNewswire Inc. Silence Therapeutics plc Fri, 05 Feb 2021 12:00 GMT Press releases Company Announcement
http://www.10gbhost.com/news-release/2021/02/05/2170616/0/en/IGM-Biosciences-to-Present-at-the-Guggenheim-Healthcare-Talks-2021-Idea-Forum-Oncology-Day.html http://www.10gbhost.com/news-release/2021/02/05/2170616/0/en/IGM-Biosciences-to-Present-at-the-Guggenheim-Healthcare-Talks-2021-Idea-Forum-Oncology-Day.html Nasdaq:IGMS US4495851085 IGM Biosciences to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day MOUNTAIN VIEW, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day on February 12, 2021 at 2:00 p.m. ET. The conference will be held in a virtual meeting format.

]]>
Fri, 05 Feb 2021 12:00 GMT 2170616 en GlobeNewswire Inc. IGM Biosciences Fri, 05 Feb 2021 12:00 GMT Calendar of Events
http://www.10gbhost.com/news-release/2021/02/05/2170618/0/en/Orchard-Therapeutics-Announces-150-Million-Strategic-Financing.html http://www.10gbhost.com/news-release/2021/02/05/2170618/0/en/Orchard-Therapeutics-Announces-150-Million-Strategic-Financing.html Nasdaq:ORTX US68570P1012 Orchard Therapeutics Announces $150 Million Strategic Financing Strengthened Financial Position Supports Execution into the First Half of 2023]]> Fri, 05 Feb 2021 12:00 GMT 2170618 en GlobeNewswire Inc. Orchard Therapeutics (Europe) Limited Fri, 05 Feb 2021 12:00 GMT Financing Agreements http://www.10gbhost.com/news-release/2021/02/05/2170590/0/en/Vor-Biopharma-Announces-Pricing-of-Initial-Public-Offering.html http://www.10gbhost.com/news-release/2021/02/05/2170590/0/en/Vor-Biopharma-Announces-Pricing-of-Initial-Public-Offering.html Nasdaq:VOR US9290331084 Vor Biopharma Announces Pricing of Initial Public Offering CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced the pricing of its initial public offering of 9,828,017 shares of its common stock at a price to the public of $18.00 per share. The gross proceeds to Vor from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by Vor, are expected to be approximately $176.9 million. In addition, Vor has granted the underwriters a 30-day option to purchase up to an additional 1,474,202 shares of its common stock at the initial public offering price, less the underwriting discounts and commissions. All of the shares of common stock are being offered by Vor.

]]>
Fri, 05 Feb 2021 11:33 GMT 2170590 en GlobeNewswire Inc. Vor Biopharma Fri, 05 Feb 2021 11:34 GMT Initial Public Offerings
http://www.10gbhost.com/news-release/2021/02/05/2170460/0/en/Trading-by-management-and-close-relations-of-management.html http://www.10gbhost.com/news-release/2021/02/05/2170460/0/en/Trading-by-management-and-close-relations-of-management.html Copenhagen:NZYM B DK0060336014 Trading by management and close relations of management Please read the full announcement in?PDF

]]>
Fri, 05 Feb 2021 07:13 GMT 2170460 en GlobeNewswire Inc. Novozymes A/S Fri, 05 Feb 2021 07:13 GMT Insider's Buy/Sell European Regulatory News
http://www.10gbhost.com/news-release/2021/02/05/2170447/0/en/Tiziana-Life-Sciences-plc-Tiziana-or-the-Company-Appointment-of-Director.html http://www.10gbhost.com/news-release/2021/02/05/2170447/0/en/Tiziana-Life-Sciences-plc-Tiziana-or-the-Company-Appointment-of-Director.html Nasdaq:TLSA LSE:TILS.L US88875G1013 Tiziana Life Sciences plc ("Tiziana" or the "Company") -?Appointment of Director NEW YORK and LONDON, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces the appointment of Dr. Thomas Adams, Ph.D. as an executive director.

]]>
Fri, 05 Feb 2021 07:00 GMT 2170447 en GlobeNewswire Inc. Tiziana Life Sciences Plc Fri, 05 Feb 2021 07:00 GMT Directors and Officers
http://www.10gbhost.com/news-release/2021/02/05/2170456/0/en/Infant-Bacterial-Therapeutics-AB-publ-Interim-Management-Statement-January-1-December-31-2020.html http://www.10gbhost.com/news-release/2021/02/05/2170456/0/en/Infant-Bacterial-Therapeutics-AB-publ-Interim-Management-Statement-January-1-December-31-2020.html Stockholm:IBT B SE0008015259 Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2020 Message from the CEO

]]>
Fri, 05 Feb 2021 07:00 GMT 2170456 en GlobeNewswire Inc. Infant Bacterial Therapeutics AB Fri, 05 Feb 2021 07:01 GMT Earnings Releases and Operating Results European Regulatory News Infant Bacterial Therapeutics IBT financial report premature infants preterm Orphan drug Infant Bacterial Therapeutics IBT financial report premature infants preterm Orphan drug
http://www.10gbhost.com/news-release/2021/02/05/2170456/0/sv/Infant-Bacterial-Therapeutics-AB-publ-IBT-Del%C3%A5rsrapport-1-januari-31-december-2020.html http://www.10gbhost.com/news-release/2021/02/05/2170456/0/sv/Infant-Bacterial-Therapeutics-AB-publ-IBT-Del%C3%A5rsrapport-1-januari-31-december-2020.html Stockholm:IBT B SE0008015259 Infant Bacterial Therapeutics AB (publ), (IBT) Del?rsrapport 1 januari – 31 december 2020 VD Kommenterar

]]>
Fri, 05 Feb 2021 07:00 GMT 2170456 sv GlobeNewswire Inc. Infant Bacterial Therapeutics AB Fri, 05 Feb 2021 07:01 GMT Earnings Releases and Operating Results European Regulatory News Infant Bacterial Therapeutics IBT financial report premature infants preterm Orphan drug Infant Bacterial Therapeutics IBT financial report premature infants preterm Orphan drug
http://www.10gbhost.com/news-release/2021/02/05/2170430/0/en/Santhera-Completes-Capital-Increase-for-Financing-Arrangements.html http://www.10gbhost.com/news-release/2021/02/05/2170430/0/en/Santhera-Completes-Capital-Increase-for-Financing-Arrangements.html SWX:SANN CH0027148649 2428 2664 2701 Santhera Completes Capital Increase for Financing Arrangements
Pratteln, Switzerland, February?5, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces that it has issued 1,600,000 treasury shares. The number of shares recorded in the commercial register has been increased to 21,029,696 shares.

]]>
Fri, 05 Feb 2021 06:00 GMT 2170430 en GlobeNewswire Inc. Santhera Pharmaceuticals Holding AG Fri, 05 Feb 2021 06:00 GMT Press releases
亚洲精品私拍国产在线播放_亚洲综合区图片小说区_亚洲日本欧美日韩高观看